GlassScriptPhysician profile
Hiren Joshi
NPI 1316268469
$1,906.77
in general payments reported to CMS, 2019-2025
15 companies · $562 in 2025
The $562 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.87 · 2021: $16.97 · 2022: $174 · 2023: $359 · 2024: $755 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643 · Education: $33.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.62 |
| Education | $33.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $877.19 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $226.51 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $151.80 | 2025 | Krystexxa, Tavneos |
| Medtronic, INC. | $120.58 | 2024 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $74.62 | 2022 | |
| Novartis Pharmaceuticals Corporation | $69.80 | 2024-2025 | |
| Vifor Pharma, INC. | $67.61 | 2023-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $60.19 | 2023-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $57.27 | 2024-2025 | |
| Horizon Therapeutics Plc | $52.57 | 2023 | Krystexxa |
| Novo Nordisk INC | $48.03 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $33.09 | 2024-2025 | Lupkynis |
| Cormedix INC. | $26.16 | 2024 | Defencath |
| Apellis Pharmaceuticals, INC. | $21.85 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.50 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiren Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.